Abstract
1. Elimination rates of phenylbutazone and warfarin after single oral doses in human volunteers, and steady-state plasma concentrations of these drugs in patients have been measured before, during and after administration of allopurinol.
2. Allopurinol, in usual clinical doses, had no significant influence on the elimination rate of either drug in the group of volunteers as a whole although in a few individuals an apparent inhibitory effect was observed.
3. No significant changes in the steady-state plasma concentrations of either phenylbutazone or warfarin were observed in patients during the administration of allopurinol.
4. It is concluded that although allopurinol may have an apparent inhibitory effect on drug elimination in a few individuals, its administration to most patients on anticoagulant therapy is unlikely to alter dose requirements.
Full text
PDFSelected References
These references are in PubMed. This may not be the complete list of references from this article.
- BURNS J. J., ROSE R. K., CHENKIN T., GOLDMAN A., SCHULERT A., BRODIE B. B. The physiological disposition of phenylbutazone (butazolidin) in man and a method for its estimation in biological material. J Pharmacol Exp Ther. 1953 Nov;109(3):346–357. [PubMed] [Google Scholar]
- BURNS J. J., YU T. F., DAYTON P. G., GUTMAN A. B., BRODIE B. B. Biochemical pharmacological considerations of phenylbutazone and its analogues. Ann N Y Acad Sci. 1960 Mar 30;86:253–291. doi: 10.1111/j.1749-6632.1960.tb42810.x. [DOI] [PubMed] [Google Scholar]
- Breckenridge A., Orme M. L. The plasma half lives and the pharmacological effect of the enantiomers of warfarin in rats. Life Sci II. 1972 Apr 8;11(7):337–345. doi: 10.1016/0024-3205(72)90073-2. [DOI] [PubMed] [Google Scholar]
- Corn M., Berberich R. Rapid fluorometric assay for plasma warfarin. Clin Chem. 1967 Feb;13(2):126–131. [PubMed] [Google Scholar]
- Fox R. M., Royse-Smith D., O'Sullivan W. J. Orotidinuria induced by allopurinol. Science. 1970 May 15;168(3933):861–862. doi: 10.1126/science.168.3933.861. [DOI] [PubMed] [Google Scholar]
- Fox R. M., Wood M. H., O'Sullivan W. J. Studies on the coordinate activity and liability of orotidylate phosphoribosyltransferase and decarboxylase in human erythrocytes, and the effects of allopurinol administration. J Clin Invest. 1971 May;50(5):1050–1060. doi: 10.1172/JCI106576. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kater R. M., Tobon F., Iber F. L. Increased rate of tolbutamide metabolism in alcoholic patients. JAMA. 1969 Jan 13;207(2):363–365. [PubMed] [Google Scholar]
- Kelley W. N., Beardmore T. D. Allopurinol: alteration in pyrimidine metabolism in man. Science. 1970 Jul 24;169(3943):388–390. doi: 10.1126/science.169.3943.388. [DOI] [PubMed] [Google Scholar]
- Lewis R. J., Trager W. F. The metabolic fate of warfarin: studies on the metabolites in plasma. Ann N Y Acad Sci. 1971 Jul 6;179:205–212. doi: 10.1111/j.1749-6632.1971.tb46900.x. [DOI] [PubMed] [Google Scholar]
- Vesell E. S., Page J. G. Genetic control of drug levels in man: phenylbutazone. Science. 1968 Mar 29;159(3822):1479–1480. doi: 10.1126/science.159.3822.1479. [DOI] [PubMed] [Google Scholar]
- Vesell E. S., Passananti G. T., Greene F. E. Impairment of drug metabolism in man by allopurinol and nortriptyline. N Engl J Med. 1970 Dec 31;283(27):1484–1488. doi: 10.1056/NEJM197012312832703. [DOI] [PubMed] [Google Scholar]
- Whittaker J. A., Evans D. A. Genetic control of phenylbutazone metabolism in man. Br Med J. 1970 Nov 7;4(5731):323–328. doi: 10.1136/bmj.4.5731.323. [DOI] [PMC free article] [PubMed] [Google Scholar]